Zimmer Biomet
872 hedge funds and large institutions have $19B invested in Zimmer Biomet in 2018 Q4 according to their latest regulatory filings, with 97 funds opening new positions, 255 increasing their positions, 333 reducing their positions, and 107 closing their positions.
1.04% more ownership
Funds ownership: 91.74% → 92.79% (+1%)
9% less first-time investments, than exits
New positions opened: 97 | Existing positions closed: 107
2% less funds holding
Funds holding: 892 → 872 (-20)
6% less funds holding in top 10
Funds holding in top 10: 17 → 16 (-1)
17% less call options, than puts
Call options by funds: $59.2M | Put options by funds: $71.6M
20% less capital invested
Capital invested by funds: $23.8B → $19B (-$4.82B)
23% less repeat investments, than reductions
Existing positions increased: 255 | Existing positions reduced: 333
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$274M |
| 2 |
American Century Companies
Kansas City,
Missouri
|
+$118M |
| 3 |
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
|
+$113M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$61.4M |
| 5 |
Boston Partners
Boston,
Massachusetts
|
+$53.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HM
HealthCor Management
New York
|
-$218M |
| 2 |
Millennium Management
New York
|
-$151M |
| 3 |
BM
Bridger Management
New York
|
-$92.7M |
| 4 |
FAM
Fred Alger Management
New York
|
-$87M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$80.8M |
ZBH Hedge Fund Activity: Q4 2018 in Review
872 of the 4,489 institutional investors tracked by Wall St. Rank reported a position in Zimmer Biomet (ZBH) for Q4 2018, worth a combined $19B — down 20% from $23.8B a quarter earlier.
Sellers outnumbered buyers: 107 funds closed out of ZBH and 97 opened new positions — a net loss of 10 holders — while 333 trimmed existing stakes and 255 added.
The largest buyer was T. Rowe Price Associates, adding an estimated $274M. The largest seller was HealthCor Management, cutting an estimated $218M.
- 872 institutional investors held Zimmer Biomet (ZBH) as of Q4 2018, down from 892 in Q3 2018.
- Funds reported $19B of Zimmer Biomet stock for Q4 2018, down 20% quarter-over-quarter.
- 97 funds opened new Zimmer Biomet positions in Q4 2018 and 107 closed out, a net change of -10 holders.
- The largest Zimmer Biomet buyer in Q4 2018 was T. Rowe Price Associates, an estimated $274M added.
- The largest Zimmer Biomet seller in Q4 2018 was HealthCor Management, an estimated $218M sold.
Based on aggregated 13F filings for Q4 2018.